Literature DB >> 27995486

Clostridium difficile infection: Updates in management.

Raseen Tariq1, Sahil Khanna2.   

Abstract

Clostridium difficile was first identified in 1978 as a diarrhea-causing bacterium in humans. In the last three decades, C. difficile infection (CDI) has reached an epidemic state, both in health care and community settings worldwide. There has been substantial progress in the field of CDI, including identification of novel risk factors, presence of CDI in individuals not considered at risk previously, and treatment options including new drugs, monoclonal antibodies, and fecal microbiota transplantation. This review discusses epidemiology, novel and traditional risk factors, and updates in management for CDI.

Entities:  

Keywords:  Clostridium difficile infection; Management; Risk factors

Mesh:

Substances:

Year:  2016        PMID: 27995486     DOI: 10.1007/s12664-016-0719-z

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  76 in total

1.  Proton pump inhibitors and risk for recurrent Clostridium difficile infection.

Authors:  Amy Linsky; Kalpana Gupta; Elizabeth V Lawler; Jennifer R Fonda; John A Hermos
Journal:  Arch Intern Med       Date:  2010-05-10

Review 2.  Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.

Authors:  Jason W Lancaster; S James Matthews
Journal:  Clin Ther       Date:  2012-01       Impact factor: 3.393

3.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.

Authors:  Mary Y Hu; Kianoosh Katchar; Lorraine Kyne; Seema Maroo; Sanjeev Tummala; Valley Dreisbach; Hua Xu; Daniel A Leffler; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2008-12-13       Impact factor: 22.682

Review 4.  Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

Authors:  Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun
Journal:  Am J Gastroenterol       Date:  2013-02-26       Impact factor: 10.864

Review 5.  Tests for the diagnosis of Clostridium difficile infection: the next generation.

Authors:  Karen C Carroll
Journal:  Anaerobe       Date:  2011-03-03       Impact factor: 3.331

6.  Rifaximin in the treatment of recurrent Clostridium difficile infection.

Authors:  E Mattila; P Arkkila; P S Mattila; E Tarkka; P Tissari; V-J Anttila
Journal:  Aliment Pharmacol Ther       Date:  2012-10-24       Impact factor: 8.171

7.  Clinical factors associated with development of severe-complicated Clostridium difficile infection.

Authors:  Raina Shivashankar; Sahil Khanna; Patricia P Kammer; W Scott Harmsen; Alan R Zinsmeister; Larry M Baddour; Darrell S Pardi
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-20       Impact factor: 11.382

8.  Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses.

Authors:  Daniela Baldoni; Marcelo Gutierrez; Wolfgang Timmer; Jasper Dingemanse
Journal:  J Antimicrob Chemother       Date:  2013-10-08       Impact factor: 5.790

9.  Incidence of Clostridium difficile associated diarrhoea in a tertiary care hospital.

Authors:  Mala V Kaneria; Sonia Paul
Journal:  J Assoc Physicians India       Date:  2012-11

Review 10.  Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.

Authors:  Oliver A Cornely; Dilip Nathwani; Cristina Ivanescu; Olatunji Odufowora-Sita; Peny Retsa; Isaac A O Odeyemi
Journal:  J Antimicrob Chemother       Date:  2014-07-28       Impact factor: 5.790

View more
  1 in total

1.  Clostridium difficile infection: Is there a change in the underlying factors? Inflammatory bowel disease and Clostridium difficile.

Authors:  Sibel Bolukcu; Ismail Necati Hakyemez; Bilge Sumbul Gultepe; Gulay Okay; Bulent Durdu; Meliha Meric Koc; Turan Aslan
Journal:  Saudi J Gastroenterol       Date:  2019 Nov-Dec       Impact factor: 2.485

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.